Poor
Not Aligned
Patient Risk:
Low
Summary
The AI statements largely discuss generic chemistry or unsupported intermediate synthesis and do not accurately match CRESTOR FDA label claims for indications, dosing, contraindications, warnings, interactions, or safety. Only high-level, mechanism/class-level statements are broadly consistent, but they are not sufficiently label-supported and contain multiple unsupported non-label claims.
Category Scores
Accurate Statements
Rosuvastatin belongs to the class of drugs known as HMG-CoA reductase inhibitors.
Supported by label mechanism of action: “CRESTOR is an inhibitor of HMG‑CoA reductase...” (Section 12.1).
Unsupported Statements
Rosuvastatin is a statin medication used to treat high cholesterol.
The provided label excerpt supports use to reduce LDL-C (as an adjunct to diet and exercise) but does not explicitly state “to treat high cholesterol” as phrased; treat as partially aligned at best.
Rosuvastatin is used to reduce the risk of cardiovascular disease.
The label excerpt specifies reduction of risk of major adverse cardiovascular events in adults at increased risk for CV events; the AI statement is broader (“cardiovascular disease”) than the label wording.
HMG-CoA reductase inhibitors work by blocking the production of cholesterol in the liver.
The label excerpt does not provide this specific mechanism detail; only general “inhibitor of HMG‑CoA reductase” is shown.
Rosuvastatin intermediates are essential components in the synthesis of rosuvastatin.
Not addressed in the provided CRESTOR prescribing information sections; absent from label.
Rosuvastatin intermediates serve as building blocks that allow chemists to create rosuvastatin through a series of chemical reactions.
Not addressed in the provided CRESTOR prescribing information; absent from label.
The synthesis of rosuvastatin intermediates involves a step to synthesize the lactone ring via reaction of a lactone with a Grignard reagent.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
The synthesis of rosuvastatin intermediates involves introduction of a side chain to the lactone ring through a series of chemical reactions.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
The synthesis of rosuvastatin intermediates involves formation of the amide bond via condensation reaction between the lactone ring and an amine.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
A lactone intermediate is formed through reaction of a lactone with a Grignard reagent.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
A side chain intermediate is formed through introduction of a side chain to the lactone ring.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
An amide intermediate is formed through formation of the amide bond between the lactone ring and an amine.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
Rosuvastatin intermediates are used to synthesize rosuvastatin.
Manufacturing/chemistry details not present in the provided prescribing information; absent from label.
Rosuvastatin intermediates are used for development of new statins.
Not addressed in the provided CRESTOR prescribing information; absent from label.
Rosuvastatin intermediates are used in research and development to study the properties and behavior of statins.
Not addressed in the provided CRESTOR prescribing information; absent from label.
Synthesizing rosuvastatin intermediates can result in low yields.
Manufacturing performance statements not present in the prescribing information; absent from label.
Synthesizing rosuvastatin intermediates may involve purity issues requiring additional purification steps.
Manufacturing performance/purity statements not present in the prescribing information; absent from label.
Some chemical reactions involved in synthesizing rosuvastatin intermediates can be hazardous.
Manufacturing/chemical hazard statements not present in the prescribing information; absent from label.
Optimization of reaction conditions can improve yields and purity in synthesizing rosuvastatin intermediates.
Manufacturing optimization statements not present in the prescribing information; absent from label.
Use of alternative routes can reduce the risk of low yields and purity issues in synthesizing rosuvastatin intermediates.
Manufacturing process statements not present in the prescribing information; absent from label.
Implementation of safety protocols can minimize the risk of hazardous reactions in synthesizing rosuvastatin intermediates.
Manufacturing process/safety statements not present in the prescribing information; absent from label.
Contradictions
Important Omissions
CRESTOR labeled indication details (e.g., specific indication language for major adverse CV events and LDL-C indications) and any labeled dosing guidance (dose range, administration instructions, missed dose guidance, antacid timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains no direct patient dosing, contraindication, or safety-warning instructions. However, it includes multiple unsupported statements unrelated to label and does not provide required prescribing information elements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are absent from the CRESTOR prescribing information (especially detailed chemistry/intermediates and manufacturing-process assertions), and the response omits key labeled prescribing elements (dosing/administration and precise indication wording).
Suggested Improvement
Restrict claims to content supported by the CRESTOR label excerpts provided (e.g., labeled indications, approved dosing/administration directions, contraindications, boxed/warning statements, and labeled interaction/monitoring guidance) and remove non-label chemistry/manufacturing intermediary statements.